ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 818

HLA-B*0801 Is Strongly Associated With Asymmetrical Sacroiliitis and HLA-B*27 With Symmetrical Involvement In Psoriatic Arthritis: Results Of a Long-Term Follow-Up Study Examining Clinical and Genetic Predictors Of Radiographic Sacroiliitis

Muhammad Haroon1, Agnes Szentpetery2, Phil Gallagher3, Robert Winchester4 and Oliver FitzGerald1, 1Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, 2Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, 3Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, 4Dept of Medicine & Pathology, Columbia University, New York, NY

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Therapeutics and Outcomes in Psoriatic Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Psoriatic arthritis (PsA) is characterised by involvement of both the appendicular and axial skeleton.  Little is known about the clinical predictors of sacroiliitis (SI), especially regarding underlying patient’s characteristics, life style, correlation with skin disease and with severity of psoriatic disease. The objectives of our study were: 1) To investigate the prevalence of SI in an ethnically homogenous cohort of established PsA, 2) to identify clinical and genetic predictors of SI in patients with PsA, 3) to describe different radiographic patterns of SI and their potential associations with clinical and genetic characteristics.

Methods: A cohort of 283 PsA patients, fulfilling CASPAR criteria, was included. Following informed consent, patients underwent a detailed skin and rheumatologic assessment including PASI, body surface area for Psoriasis (PsO), CRP, ESR, smoking, BMI status, alcohol intake, education status, family history of PsO and/or PsA, PsA duration, age of PsO/PsA onset, enthesitis, dactylitis, erosions, osteolysis, arthritis mutilans, clinically deformed joints, PsO and/or PsA requiring TNFi treatment, HAQ, DLQI, Bristol Rheumatoid Arthritis Fatigue Numeric Rating Scale (BRAF-NRS), and EQ5D. In addition, HLA-B*27 and B*080101 status was recorded, which we have recently shown are the key genetic markers of radiographic SI (www.rheumatology.org/education/annual/2012_abstract_supplement.pdf). Unilateral or bilateral grade 2 radiographic changes were required for inclusion as having SI. SI involvement was further defined as asymmetrical when radiographic scoring grades were discordant between the 2 SI joints and as unilateral when the opposite SI joint was completely uninvolved. 

Results: 70 patients (25%) had radiographic SI; all either had present or past history of backache. Mean age of patients with SI was 51.6±11 years, and 53.5% were male. Unilateral SI was present in 14 patients (27%); bilateral SI in 38 patients (73%). Of those with bilateral involvement, SI was asymmetrical in 28 (73%) patients. HLA-B*0801 was significantly associated with asymmetrical SI, which included those with unilateral SI or asymmetrical bilateral involvement (p=0.001), and in striking contrast, HLA-B*2705 was significantly associated with bilateral symmetrical SI (p=<0.001). On backward step-wise multiple regression analysis, model predicted significant association of peripheral joint erosions (OR 1.91, p=0.03), PASI maximum (OR 1.05, p=0.03), younger PsA age of onset (OR 0.93, p=<0.001), presence of HLA-B*0801 (OR 2.9, p=0.001) and HLA-B*2705 (OR 2.39, p=0.02) with SI. 

Conclusion: Twenty five percent of PsA patients developed SI on long-term follow up. PsA developing at younger age, severe skin PsO, peripheral joint erosions, HLA-B*0801 and HLA-B*2705 are clinical and genetic predictors for the development of SI. We report for the first time that there are two separate principal patterns of HLA antigens explaining 2 clinically distinct sub-types of radiographic SI.


Disclosure:

M. Haroon,
None;

A. Szentpetery,
None;

P. Gallagher,
None;

R. Winchester,
None;

O. FitzGerald,

Pfizer, Abbott, UCB, Roche, MSD, BMS,

2,

Janssen Pharmaceutica Product, Pfizer, Abbott, Roche, MSD, BMS,

5,

Pfizer, Abbott, UCB, Roche, Janssen,

8.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hla-b0801-is-strongly-associated-with-asymmetrical-sacroiliitis-and-hla-b27-with-symmetrical-involvement-in-psoriatic-arthritis-results-of-a-long-term-follow-up-study-examining-clinical-and-genetic/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology